CLOs on the Move

Midwest AgEnergy Group

www.midwestagenergygroup.com

 
Midwest AgEnergy Group is a North Dakota biofuels enterprise. Midwest AgEnergy Group owns Blue Flint Ethanol, a 65 million gallon per year biorefinery in operation since 2007 near Underwood, N.D., and Dakota Spirit AgEnergy, a 65 million gallon per year biorefinery east of Jamestown, ND that began production in June 2015. Together with our partners, we are building a renewable energy future for the country, increasing demand for North Dakota farmers, and bringing prosperity to our communities.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Intact Vascular

Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular Systemâ„¢ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.

Bruker

Bruker is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orna Therapeutics

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna`s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Lassen Therapeutics

Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.

Anthos Therapeutics

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.